ProCE Banner Activity

CME

Identifying and Managing Patients at Risk for HBV Reactivation

Multimedia
In this video module, Leonard H. Calabrese, DO; Robert P. Perrillo, MD, FAASLD; and Andrew D. Zelenetz, MD, PhD, discuss best practices in HBV screening and prophylaxis for patients who will undergo immunosuppressive therapy.

Physicians : maximum of 1.00 AMA PRA Category 1 {Credit}

Released: October 18, 2016

Expiration: October 17, 2017

No longer available for credit.

Share

Faculty

Leonard H. Calabrese

Leonard H. Calabrese, DO

Professor of Medicine
Department of Rheumatology
Cleveland Clinic
Cleveland, Ohio

Robert P. Perrillo

Robert P. Perrillo, MD

Director of Academic Affairs, Gastroenterology and Hepatology
Ochsner Clinic Foundation
New Orleans, Louisiana

Andrew D. Zelenetz

Andrew D. Zelenetz, MD, PhD

Associate Professor, Department of Medicine
Cornell University Medical College
Chief, Lymphoma Service
Memorial Sloan-Kettering Cancer Center
New York, New York

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an independent educational grant from

Gilead

Target Audience

This program is intended for oncologists, rheumatologists, gastroenterologists, hepatologists, infectious disease physicians, and other healthcare professionals involved in the management of patients at risk for HBV reactivation.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Implement strategies to ensure that patients at risk for HBV reactivation are identified and appropriately screened
  • Apply current management guidelines and expert recommendations for the prevention and management of HBV reactivation

Faculty Disclosure

Primary Author

Leonard H. Calabrese, DO

Professor of Medicine
Department of Rheumatology
Cleveland Clinic
Cleveland, Ohio

Leonard H. Calabrese, DO, has disclosed that he has received fees for non-CME/CE services from AbbVie, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Janssen, Pfizer, and UCB.

Robert P. Perrillo, MD

Director of Academic Affairs, Gastroenterology and Hepatology
Ochsner Clinic Foundation
New Orleans, Louisiana

Robert P. Perrillo, MD, FAASLD, has disclosed that he has received consulting fees from Dynavax.

Andrew D. Zelenetz, MD, PhD

Associate Professor, Department of Medicine
Cornell University Medical College
Chief, Lymphoma Service
Memorial Sloan-Kettering Cancer Center
New York, New York

Andrew D. Zelenetz, MD, PhD, has disclosed that he has received funds for research support from Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Janssen, and Roche, consulting fees from Adaptive Biotechnology, Amgen, Celgene, Genentech/Roche, Gilead, GlaxoSmithKline, Hospira, Janssen, Nanostring Tech, Novartis, Portola Pharmaceuticals, and Takeda, and holds membership with a data monitoring committee with Boehringer Ingelheim.

Staff Disclosure

Staff

Megan K. Murphy, PhD

Scientific Director

Megan K. Murphy, PhD, has no real or apparent conflicts of interest to report.

Jenny Schulz, PhD

Associate Managing Editor, Hepatitis
Clinical Care Options, LLC

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan P. Topping, PhD, has no real or apparent conflicts of interest to report.

Instructions for Credit

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 18, 2016, through October 17, 2017:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ competence in identifying patients at risk of HBV reactivation, providing appropriate HBV screening, and implementing preventive therapy as appropriate.